Salubris Pharmaceuticals - Public Comps and Valuation Multiples

Salubris Pharmaceuticals Overview

About Salubris Pharmaceuticals

Shenzhen Salubris Pharmaceuticals Co Ltd is a pharmaceutical company dedicated to the research, development, and sale of medical products for cardiovascular diseases, cephalosporins, and bone resorption inhibitors. Its products mainly focus on the areas of cardio-cerebral vascular disease, diabetes, complications, anti-tumor, and orthopedics. Its business lines include high-end chemical drugs, biological drugs, and medical devices. Its businesses are located in China, the United States, Germany, France, and Japan, and other countries and regions.

Founded

2007

HQ

Employees

3.6K+

Website

salubris.com

Sectors

Drug Development & Therapeutics
Medical Devices
HealthTech
DeepTech

Financials

LTM Revenue $614M

LTM EBITDA $182M

EV

$8.7B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Salubris Pharmaceuticals Financials

As of September 2025, Salubris Pharmaceuticals reported last 12-month revenue of $614M and EBITDA of $182M.

In the same period, Salubris Pharmaceuticals generated $452M in LTM gross profit and $91.6M in net income.

See Salubris Pharmaceuticals valuation multiples based on analyst estimates

Salubris Pharmaceuticals P&L

In the most recent fiscal year, Salubris Pharmaceuticals reported revenue of $563M and EBITDA of $144M.

Salubris Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Salubris Pharmaceuticals valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$614M	XXX	$563M	XXX	XXX	XXX
Gross Profit	$452M	XXX	$409M	XXX	XXX	XXX
Gross Margin	74%	XXX	73%	XXX	XXX	XXX
EBITDA	$182M	XXX	$144M	XXX	XXX	XXX
EBITDA Margin	30%	XXX	26%	XXX	XXX	XXX
EBIT	$106M	XXX	$108M	XXX	XXX	XXX
EBIT Margin	17%	XXX	19%	XXX	XXX	XXX
Net Profit	$91.6M	XXX	$84.4M	XXX	XXX	XXX
Net Margin	15%	XXX	15%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Salubris Pharmaceuticals including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $614M. EBITDA for the last twelve months was $182M. In the most recent fiscal year, Salubris Pharmaceuticals achieved $563M in revenue and $144M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$614M	Analyst estimates available to subscribers	$563M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$452M	Analyst estimates available to subscribers	$409M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	73.7% gross margin	Analyst estimates available to subscribers	72.6% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$182M	Analyst estimates available to subscribers	$144M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	29.7% EBITDA margin	Analyst estimates available to subscribers	25.5% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$106M	Analyst estimates available to subscribers	$108M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	17.4% EBIT margin	Analyst estimates available to subscribers	19.2% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$91.6M	Analyst estimates available to subscribers	$84.4M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	14.9% net profit margin	Analyst estimates available to subscribers	15.0% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Salubris Pharmaceuticals

This financial data table provides comprehensive performance metrics for Salubris Pharmaceuticals, a company based in China. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Salubris Pharmaceuticals generated $614M in revenue over the last twelve months.
The company achieved $182M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $452M.
Net income over the last twelve months reached $91.6M.

Fiscal Year Performance

In the most recent fiscal year, Salubris Pharmaceuticals reported $563M in total revenue.
Fiscal year EBITDA was $144M.
The company maintained a gross profit margin of 72.6% in the most recent fiscal year.
EBITDA margin for the fiscal year was 25.5%.
Net profit margin reached 15.0% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Salubris Pharmaceuticals. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Salubris Pharmaceuticals Stock Performance

Salubris Pharmaceuticals has current market cap of CNY 62.9B (or $8.8B), and EV of CNY 61.8B (or $8.7B).

Market Cap Evolution

Salubris Pharmaceuticals Stock Data

As of October 17, 2025, Salubris Pharmaceuticals's stock price is CNY 56 (or $8).

See Salubris Pharmaceuticals trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$8.7B	$8.8B	XXX	XXX	XXX	XXX	$0.08

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Salubris Pharmaceuticals Valuation Multiples

Salubris Pharmaceuticals's trades at 15.4x EV/Revenue multiple, and 60.3x EV/EBITDA.

See valuation multiples for Salubris Pharmaceuticals and 15K+ public comps

Salubris Pharmaceuticals Financial Valuation Multiples

As of October 17, 2025, Salubris Pharmaceuticals has market cap of $8.8B and EV of $8.7B.

Equity research analysts estimate Salubris Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Salubris Pharmaceuticals has a P/E ratio of 96.3x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$8.8B	XXX	$8.8B	XXX	XXX	XXX
EV (current)	$8.7B	XXX	$8.7B	XXX	XXX	XXX
EV/Revenue	14.1x	XXX	15.4x	XXX	XXX	XXX
EV/EBITDA	47.6x	XXX	60.3x	XXX	XXX	XXX
EV/EBIT	81.4x	XXX	80.2x	XXX	XXX	XXX
EV/Gross Profit	19.2x	XXX	n/a	XXX	XXX	XXX
P/E	96.3x	XXX	104.5x	XXX	XXX	XXX
EV/FCF	n/a	XXX	110.1x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Salubris Pharmaceuticals Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Salubris Pharmaceuticals Margins & Growth Rates

Salubris Pharmaceuticals's last 12 month revenue growth is 19%

Salubris Pharmaceuticals's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.

Salubris Pharmaceuticals's rule of 40 is 48% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Salubris Pharmaceuticals's rule of X is 76% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Salubris Pharmaceuticals and other 15K+ public comps

Salubris Pharmaceuticals Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	19%	XXX	16%	XXX	XXX	XXX
EBITDA Margin	30%	XXX	26%	XXX	XXX	XXX
EBITDA Growth	10%	XXX	14%	XXX	XXX	XXX
Rule of 40	48%	XXX	44%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	76%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.2M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.1M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	24%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	10%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	53%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial